• Sign In
  • Home
  • News
    • Politics
      • White House
      • Senate
      • House
      • Campaigns
  • Policy
  • 2026 Election
  • Opinion
    • Editorials
    • Op-Eds
  • In Focus
  • Restoring America
  • Magazine
  • Watch
  • Sponsored
    • Powering Progress
    • ASAE – Association Leadership
    • Examining Tax Reform
    • Fix TSCA
    • National Parks
    • Inside the Corn Belt
  • TWS Archive
Search
LogoWashington Examiner
Subscribe
LogoWashington Examiner
Sign in
Subscribe
  • News
    • Politics
      • Trump Administration
      • White House
      • Senate
      • House
      • Campaigns
    • Business
    • World
    • Investigations
    • Justice
    • Supreme Court
    • Crime
    • Entertainment
    • Washington Secrets
  • Policy
    • Defense
    • National Security
    • Energy and Environment
    • Education
    • Immigration
    • Finance and Economy
    • Healthcare
    • Foreign Policy
    • Tech
    • Infrastructure
    • Space
  • 2026 Election
  • Trump Administration
  • IN FOCUS
  • Commentary
    • Columnists
    • Editorials
    • Think Tanks
    • Beltway Confidential
    • Op-Eds
  • Restoring America
    • Patriotism and Unity
    • Faith, Freedom, and Self-Reliance
    • Courage, Strength, and Optimism
    • Equality, Not Elitism
    • Community and Family
    • Fairness and Justice
    • Mission
  • Watch
  • Magazine
    • Magazine
    • Quarterly Briefing
    • Archives
    • Games
  • Sponsored
    • Powering Progress
    • ASAE – Association Leadership
    • National Parks
    • Examining Tax Reform
    • Fix TSCA
    • Inside the Corn Belt
  • Newsletters
More
    Home Tags Pharmaceutical Industry

    Tag: Pharmaceutical Industry

    St. James Terminal,  a U.S. Department of Energy owned marine unloading and distribution point for crude oil located southwest of Baton Rouge, La., is shown in this file photo. (AP Photo/U.S. Department of Energy)
    Healthcare

    House seeks to sell oil reserves to fast-track health cures

    Robert King -
    May 21, 2015 3:14 pm
    0
    Healthcare

    Who will foot the bill for House ‘cures’ measure?

    Robert King -
    May 20, 2015 9:00 am
    0
    The pharmaceutical industry has taken heat from Congress and states over the past year for high-cost specialty drugs that insurers and public health programs such as Medicare are struggling to afford.
    Healthcare

    Pressure mounts on drug makers’ price claims

    Robert King -
    May 17, 2015 9:00 am
    0
    The drug that got the most money from Part D was Sovaldi, which the agency paid out $3.1 billion in 2014. (AP Photo/Matt Rourke)
    Healthcare

    House cures bill advances on heavy bipartisan support

    Robert King -
    May 14, 2015 4:36 pm
    0
    In this Thursday, Feb. 28, 2013 photo, Merck scientist Pascale Nantermet conducts research to discover new HIV drugs in West Point, Pa. (AP Photo/Matt Rourke)
    Healthcare

    House caves on exclusivity perks for drugs

    Robert King -
    May 13, 2015 4:14 pm
    0
    La. AG Caldwell accusing AstraZeneca of preventing generic drug from hitting market
    Healthcare

    La. AG Caldwell accusing AstraZeneca of preventing generic drug from hitting market

    LocalLabs News Service -
    May 13, 2015 12:43 pm
    0
    Health and Human Services Director Sylvia Mathews Burwell testifies on Capitol Hill, Thursday, April 23, 2015, before the Senate Appropriations Committee, on the proposed budget estimates and justification for the department. (Graeme Jennings/Examiner)
    Columnists

    Latest Democratic ‘war on women’ campaign, fueled by pharma cash

    Timothy P. Carney -
    May 12, 2015 10:00 pm
    0
    Lawsuit: Pharmaceutical firm illegally inflated its worth

    Lawsuit: Pharmaceutical firm illegally inflated its worth

    LocalLabs News Service -
    May 12, 2015 5:37 pm
    0
    Governments that sign on to the trade deal could be forced to grant pharmaceutical companies additional patents for changes to their products, even if a change doesn't do anything, Doctors Without Borders said. The process is called evergreening and is a way to delay entry of much cheaper generic copycat versions of a brand name drug. (Getty Image)
    Healthcare

    Humanitarian groups blast trade deal

    Robert King -
    May 12, 2015 9:00 am
    0
    Vitamin Shoppe agrees to stop selling products with BMPEA

    Vitamin Shoppe agrees to stop selling products with BMPEA

    LocalLabs News Service -
    May 11, 2015 7:09 pm
    0
    1...141142143...157Page 142 of 157
    LogoWashington Examiner
    Do Not Sell or Share My Personal Information
    Facebook
    Twitter
    Youtube

    NEWS

    • Politics
      • White House
      • Senate
      • House
      • Campaigns
    • Business
    • World
    • Investigations
    • Justice
    • Supreme Court
    • Crime
    • Washington Secrets
    • Entertainment
    • Sports

    POLICY

    • Defense
    • National Security
    • Energy
    • Immigration
    • Finance and Economy
    • Healthcare
    • Foreign Policy
    • Tech
    • Infrastructure
    • Space

    COMMENTARY

    • Columnists
    • Editorials
    • Think Tanks
    • Beltway Confidential
    • Op-Eds

    RESTORING AMERICA

    • Patriotism and Unity
    • Faith, Freedom, and Self-Reliance
    • Courage, Strength, and Optimism
    • Equality, Not Elitism
    • Community and Family
    • Fairness and Justice
    • Mission
    • WATCH
    • IN FOCUS
    • NEWSLETTERS
    • MAGAZINE ARCHIVE
    • Policies and Standards
    • Terms Of Service
    • Subscription Terms of Use
    • Privacy Policy
    • Your Privacy Choices
    • Transparency In Coverage
    • Advertise
    • Subscribe
    • Contact
    • Careers
    • Staff
    • About Examiner
    • Facebook
    • Twitter
    • © Copyright 2026. Washington Examiner. All Rights Reserved.